Property Summary

NCBI Gene PubMed Count 454
PubMed Score 2084.57
PubTator Score 1245.08

Knowledge Summary


No data available


  Disease Sources (6)

Disease Target Count P-value
posterior fossa group A ependymoma 1511 8.17595027667027E-23
pilocytic astrocytoma 3086 4.5537191619304E-15
adult high grade glioma 2148 7.73776917477953E-8
ovarian cancer 8492 1.22368392989602E-6
glioblastoma 5572 1.59392226126067E-6
atypical teratoid / rhabdoid tumor 4369 2.47528511468647E-5
hepatocellular carcinoma 550 7.79546534416247E-5
medulloblastoma, large-cell 6234 2.23740593704723E-4
medulloblastoma 1524 2.68870245325116E-4
gastric cancer 436 6.50024204774752E-4
astrocytic glioma 2241 0.00106636258622195
lung cancer 4473 0.00119570042560084
Pick disease 1893 0.00122402108151146
Multiple myeloma 1328 0.00157242910104319
oligodendroglioma 2849 0.00376126858350889
subependymal giant cell astrocytoma 2287 0.0103656490978713
Disease Target Count Z-score Confidence
Endometriosis 535 0.0 2.0
Schizophrenia 503 0.0 1.0
Disease Target Count Z-score Confidence
Intellectual disability 573 3.004 1.5
Disease Target Count
Takenouchi-Kosaki syndrome 1


  Differential Expression (16)

Disease log2 FC p
gastric cancer -1.200 0.001
hepatocellular carcinoma -1.200 0.000
Multiple myeloma 1.200 0.002
astrocytic glioma -3.400 0.001
posterior fossa group A ependymoma -4.400 0.000
oligodendroglioma -3.300 0.004
glioblastoma -3.700 0.000
medulloblastoma -1.800 0.000
atypical teratoid / rhabdoid tumor -3.600 0.000
medulloblastoma, large-cell -2.500 0.000
lung cancer -2.300 0.001
adult high grade glioma -3.700 0.000
pilocytic astrocytoma -4.200 0.000
subependymal giant cell astrocytoma -2.967 0.010
Pick disease -2.200 0.001
ovarian cancer -1.400 0.000


Accession P60953 P21181 P25763 Q7L8R5 Q9UDI2
Symbols TKS



4YC7   5CJP   1CEE   2WM9   2WMN   2WMO   4JS0   1AM4   1GRN   2NGR   1CF4   1A4R   1AJE   1AN0   1DOA   1E0A   1EES   1GZS   1KI1   1KZ7   1KZG   1NF3   2ASE   2DFK   2KB0   2ODB   2QRZ   3GCG   3QBV   3VHL   4DID   4ITR   4YDH   5FI1  

  Ortholog (11)

Species Source
Chimp OMA EggNOG
Macaque OMA EggNOG
Mouse OMA EggNOG Inparanoid
Rat OMA EggNOG Inparanoid
Dog OMA EggNOG Inparanoid
Opossum OMA EggNOG Inparanoid
Platypus OMA EggNOG
Chicken OMA Inparanoid
Xenopus OMA EggNOG Inparanoid
Fruitfly EggNOG Inparanoid
S.cerevisiae OMA Inparanoid

MLP Assay (3)

AID Type Active / Inconclusive / Inactive Description
588377 confirmatory 5 / 0 / 0 SAR compounds for Cdc42 probe extension project tested by Multiplex dose response to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Cdc42 wildtype, round 1
720688 other 0 / 0 / 0 Assessing protein source dependence on dose response curves of small molecule inhibitors of Ras and Ras-related GTPases specifically Cdc42 wildtype
720712 other 0 / 0 / 0 Comparison of test compound incubation dependence on dose response curves of small molecule inhibitors of Ras and Ras-related GTPases specifically Cdc42 wildtype

Gene RIF (294)

26986510 the Cdc42/Nwasp/stress fibers/YAP signal pathway may potentially play an important role in regulating podocyte apoptosis. Maintaining necessary Cdc42 would be one potent way to prevent proteinuria kidney diseases.
26926567 miR-1 bound both MALAT1 and cdc42 3'UTR directly. Further study showed that MALAT1 induced migration and invasion of breast cancer cells while reduced the level of cdc42.
26905694 Loss of FAT1 results in decreased cell adhesion and migration in fibroblasts and podocytes and the decreased migration is partially reversed by a RAC1/CDC42 activator.
26783207 Shp2 also mediates Cdc42 repression, and HDAC6 inhibition or co-suppression of ERK/myosin II promotes normal epithelial lumen phenotype without increasing Cdc42 activity.
26740622 Data suggest LPA (lysophosphatidic acid; acting via LPAR1) and endothelin activate Cdc42, concurrent with biphasic decrease in Rac1 activity, differential effects on RhoA; LPA/endothelin stim. leads to remodeling of invadosomes in melanoma cells.
26689677 Chemotactic steering and de novo polarization are both directed by locally excitable Cdc42 signals in neutrophils.
26634649 we discovered distinct predictive performance of Rac1 and Cdc42 depending on the migration modes, indicating that Rac1 and Cdc42 contribute to persistent and random migration, respectively
26558612 Data indicate enantiomer selective interaction of R-naproxen and R-ketorolac with Rho family GTPases Rac1 and Cdc42.
26549550 CDC42 is a key regulator involved in regulating the proliferation, migration and invasion of gastric cancer.
26542736 Results show that the activation of cdc42 GTP-binding protein (Cdc42) is a process of conformational changes.

AA Sequence


Text Mined References (468)

PMID Year Title
26986510 2016 Cdc42 deficiency induces podocyte apoptosis by inhibiting the Nwasp/stress fibers/YAP pathway.
26926567 2016 MALAT1 induced migration and invasion of human breast cancer cells by competitively binding miR-1 with cdc42.
26905694 2016 FAT1 mutations cause a glomerulotubular nephropathy.
26783207 2016 The Shp2-induced epithelial disorganization defect is reversed by HDAC6 inhibition independent of Cdc42.
26740622 2016 Rapid Remodeling of Invadosomes by Gi-coupled Receptors: DISSECTING THE ROLE OF Rho GTPases.
26708094 2016 Further evidence of a mutation in CDC42 as a cause of a recognizable syndromic form of thrombocytopenia.
26689677 2016 Locally excitable Cdc42 signals steer cells during chemotaxis.
26634649 2015 Distinct predictive performance of Rac1 and Cdc42 in cell migration.
26558612 2015 Novel Activities of Select NSAID R-Enantiomers against Rac1 and Cdc42 GTPases.
26549550 2016 Effects of CDC42 on the proliferation and invasion of gastric cancer cells.